Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.13% |
| 2 | Technology | 13.55% |
| 3 | Financials | 11.85% |
| 4 | Consumer Staples | 10.18% |
| 5 | Industrials | 9.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
326
Allison Transmission
ALSN
$10.1B
| $57.9M | 0.07% |
1,543,200
+561,334
| +57% | +$20.9M |
|
327
Molina Healthcare
MOH
$10.5B
| $57.6M | 0.07% |
832,250
-167,450
| -17% | -$10.3M |
|
|
BNCL
328
DELISTED
Beneficial Bancorp, Inc.
BNCL
| $57.3M | 0.07% |
3,820,870
+119,300
| +3% | +$1.84M |
|
|
POT
329
DELISTED
Potash Corp Of Saskatchewan
POT
| $57.3M | 0.07% |
3,513,263
+3,112,864
| +777% | +$51.5M |
|
330
Everest Group
EG
$14B
| $57M | 0.07% |
224,000
+49,100
| +28% | +$12.1M |
|
|
WOOF
331
DELISTED
VCA Inc.
WOOF
| $57M | 0.07% |
617,700
+375,700
| +155% | +$34.6M |
|
332
Ecopetrol
EC
$34.8B
| $56.9M | 0.07% |
6,262,700
+887,100
| +17% | +$8.3M |
|
|
AGN
333
DELISTED
Allergan plc
AGN
| $56.9M | 0.07% |
234,169
-285,900
| -55% | -$67.2M |
|
334
Teradyne
TER
$63.2B
| $56.7M | 0.07% |
1,886,700
+1,259,599
| +201% | +$42.4M |
|
335
MarketAxess Holdings
MKTX
$5.72B
| $56.6M | 0.07% |
281,438
+102,328
| +57% | +$19.6M |
|
|
MASI
336
DELISTED
Masimo
MASI
| $56.6M | 0.07% |
620,500
+191,400
| +45% | +$17.6M |
|
337
Cemex
CX
$16.2B
| $56.2M | 0.07% |
5,970,393
-916,228
| -13% | -$8.07M |
|
338
Goldman Sachs
GS
$305B
| $56.2M | 0.07% |
+253,300
| New | +$56.3M |
|
339
COPT Defense Properties
CDP
$4.17B
| $56.2M | 0.07% |
1,603,900
-359,009
| -18% | -$12.2M |
|
340
Lam Research
LRCX
$408B
| $56.2M | 0.07% |
3,970,560
+2,650,560
| +201% | +$38.9M |
|
341
HCA Healthcare
HCA
$88.4B
| $56M | 0.07% |
642,700
+360,600
| +128% | +$30.5M |
|
342
eBay
EBAY
$45.9B
| $55.9M | 0.07% |
1,601,940
-1,276,100
| -44% | -$43.7M |
|
|
TTM
343
DELISTED
Tata Motors Limited
TTM
| $55.9M | 0.07% |
1,693,600
+309,900
| +22% | +$10.8M |
|
344
Brady Corp
BRC
$4.44B
| $55.9M | 0.07% |
1,649,100
+192,000
| +13% | +$7.14M |
|
|
HOLX
345
DELISTED
Hologic
HOLX
| $55.7M | 0.07% |
1,227,118
-229,200
| -16% | -$10.1M |
|
346
Kearny Financial
KRNY
$597M
| $55M | 0.07% |
3,703,521
+262,503
| +8% | +$3.82M |
|
347
Portland General Electric
POR
$5.72B
| $54.9M | 0.07% |
1,201,300
+46,000
| +4% | +$2.12M |
|
348
Bank of Montreal
BMO
$128B
| $54.8M | 0.07% |
746,595
-158,700
| -18% | -$11.2M |
|
349
Clean Harbors
CLH
$16.7B
| $54.5M | 0.07% |
976,302
-114,700
| -11% | -$6.6M |
|
350
J.M. Smucker
SJM
$12.6B
| $54.5M | 0.07% |
+460,203
| New | +$58.2M |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, up from 15% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.